Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:ALGS NASDAQ:CLLS NASDAQ:INBX NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.10+4.9%$2.83$1.78▼$8.56$64.93M0.92226,381 shs48,286 shsALGSAligos Therapeutics$10.19+2.0%$9.22$3.76▼$46.80$62.68M2.79158,398 shs10,143 shsCLLSCellectis$3.53+11.6%$2.61$1.10▼$3.54$196.48M3.03211,324 shs181,385 shsINBXInhibrx Biosciences$28.28+6.1%$24.66$10.81▼$30.23$417.41M0.33105,791 shs94,290 shsKRYSKrystal Biotech$165.69+3.2%$147.67$122.80▼$207.84$4.76B0.66329,251 shs164,265 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+2.43%-6.05%+3.87%+31.11%-57.80%ALGSAligos Therapeutics+8.35%-8.18%+13.27%+32.32%-29.45%CLLSCellectis+2.60%+6.04%+6.04%+114.97%+37.39%INBXInhibrx Biosciences+0.45%-6.33%+15.87%+78.50%+56.86%KRYSKrystal Biotech+4.26%+11.26%+11.57%+21.25%-12.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.10+4.9%$2.83$1.78▼$8.56$64.93M0.92226,381 shs48,286 shsALGSAligos Therapeutics$10.19+2.0%$9.22$3.76▼$46.80$62.68M2.79158,398 shs10,143 shsCLLSCellectis$3.53+11.6%$2.61$1.10▼$3.54$196.48M3.03211,324 shs181,385 shsINBXInhibrx Biosciences$28.28+6.1%$24.66$10.81▼$30.23$417.41M0.33105,791 shs94,290 shsKRYSKrystal Biotech$165.69+3.2%$147.67$122.80▼$207.84$4.76B0.66329,251 shs164,265 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+2.43%-6.05%+3.87%+31.11%-57.80%ALGSAligos Therapeutics+8.35%-8.18%+13.27%+32.32%-29.45%CLLSCellectis+2.60%+6.04%+6.04%+114.97%+37.39%INBXInhibrx Biosciences+0.45%-6.33%+15.87%+78.50%+56.86%KRYSKrystal Biotech+4.26%+11.26%+11.57%+21.25%-12.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.75Moderate Buy$19.75538.13% UpsideALGSAligos Therapeutics 3.00Buy$50.00390.68% UpsideCLLSCellectis 3.00Buy$4.0013.44% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AKRYSKrystal Biotech 2.86Moderate Buy$209.0026.14% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, INBX, KRYS, ADVM, and ALGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.009/12/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/18/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.008/5/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$176.00 ➝ $166.008/5/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$219.007/25/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.007/25/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$219.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M64.93N/AN/A$3.40 per share0.91ALGSAligos Therapeutics$3.17M19.75N/AN/A($7.50) per share-1.36CLLSCellectis$49.22M3.98N/AN/A$2.36 per share1.49INBXInhibrx Biosciences$1.40M292.55$122.93 per share0.23$9.23 per share3.06KRYSKrystal Biotech$359.21M13.35$4.99 per share33.22$32.90 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)ALGSAligos Therapeutics-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)CLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9233.4616.44N/A40.85%15.21%13.81%11/3/2025 (Estimated)Latest CLLS, INBX, KRYS, ADVM, and ALGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 million8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54ALGSAligos TherapeuticsN/A6.316.31CLLSCellectis0.581.381.38INBXInhibrx Biosciences1.454.984.98KRYSKrystal BiotechN/A9.689.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ALGSAligos Therapeutics60.43%CLLSCellectis63.90%INBXInhibrx Biosciences82.46%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%ALGSAligos Therapeutics4.80%CLLSCellectis16.41%INBXInhibrx Biosciences17.09%KRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableALGSAligos Therapeutics906.15 million5.86 millionNo DataCLLSCellectis29055.58 million46.46 millionOptionableINBXInhibrx Biosciences16614.49 million12.01 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableCLLS, INBX, KRYS, ADVM, and ALGS HeadlinesRecent News About These CompaniesStrs Ohio Invests $1.24 Million in Krystal Biotech, Inc. $KRYSSeptember 18 at 3:13 AM | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Trading Up 7.5% - Here's WhySeptember 17 at 10:15 PM | marketbeat.comVoya Investment Management LLC Sells 10,100 Shares of Krystal Biotech, Inc. $KRYSSeptember 17 at 3:26 AM | marketbeat.comDystrophic Epidermolysis Bullosa: FDA Approves Labeling Changes for Topical Gene TherapySeptember 16 at 4:32 PM | medscape.comMKrystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC WainwrightSeptember 16 at 2:51 PM | marketbeat.comKrystal Biotech Stock Up on FDA Nod to Vyjuvek Label UpdateSeptember 16 at 1:55 PM | zacks.comKrystal Biotech stock jumps after FDA expands VYJUVEK labelSeptember 16 at 6:29 AM | in.investing.comKrystal Biotech gets expanded FDA approval for VyjuvekSeptember 16 at 6:29 AM | msn.comFDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering SkinSeptember 15, 2025 | benzinga.comKrystal Biotech announces FDA approval of update VYJUVEK labelSeptember 15, 2025 | msn.comKrystal Biotech Announces FDA Approval of Updated VYJUVEK® LabelSeptember 15, 2025 | globenewswire.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 365,304 Shares of Krystal Biotech, Inc. $KRYSSeptember 15, 2025 | marketbeat.comFred Alger Management LLC Purchases Shares of 3,728 Krystal Biotech, Inc. $KRYSSeptember 13, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Moderate Buy" by AnalystsSeptember 13, 2025 | americanbankingnews.com5 Best Stocks To Buy For September 2025September 12, 2025 | forbes.comTSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS)September 12, 2025 | insidermonkey.comS Squared Technology LLC Acquires 2,000 Shares of Krystal Biotech, Inc. $KRYSSeptember 11, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 9, 2025 | marketbeat.comEP Wealth Advisors LLC Acquires New Position in Krystal Biotech, Inc. $KRYSSeptember 9, 2025 | marketbeat.comEschler Asset Management LLP Buys Shares of 4,403 Krystal Biotech, Inc. $KRYSSeptember 6, 2025 | marketbeat.comTrexquant Investment LP Invests $2.37 Million in Krystal Biotech, Inc. $KRYSSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, INBX, KRYS, ADVM, and ALGS Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.10 +0.15 (+4.92%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Aligos Therapeutics NASDAQ:ALGS$10.19 +0.20 (+2.00%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Cellectis NASDAQ:CLLS$3.53 +0.37 (+11.58%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Inhibrx Biosciences NASDAQ:INBX$28.28 +1.63 (+6.10%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$165.69 +5.08 (+3.16%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
